Mechanisms and Screening for Atherosclerosis in Adults With Vasculitis.

Autor: Hendrickson MJ; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (M.J.H., Z.S.W.)., Wallace ZS; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (M.J.H., Z.S.W.).; Rheumatology and Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston (Z.S.W.).
Jazyk: angličtina
Zdroj: Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2025 Jan; Vol. 45 (1), pp. 3-10. Date of Electronic Publication: 2024 Nov 21.
DOI: 10.1161/ATVBAHA.124.319982
Abstrakt: Vascular inflammation is a hallmark of both primary systemic vasculitis and atherosclerosis. As such, cardiovascular events are common in patients with vasculitis and likely due to both direct vascular inflammation and accelerated atherosclerosis. Direct cardiac involvement is possible in all vasculitides, though more commonly described in Takayasu arteritis, polyarteritis nodosa, and eosinophilic granulomatosis with polyangiitis. Accelerated atherosclerosis has been described in Takayasu arteritis and antineutrophil cytoplasmic antibody-associated vasculitis, though there remains a paucity of data in other forms of vasculitis. Multiple screening and management approaches for cardiovascular risk in people with vasculitis have been proposed, though evidence-based guidelines are lacking. In this review, we discuss the latest evidence in epidemiology, mechanisms, and screening for atherosclerosis in patients with primary systemic vasculitides.
Competing Interests: Z.S. Wallace reports research support from Amgen, Bristol-Myers Squibb, and Principia/Sanofi and consulting fees from Zenas Biopharma, Amgen, Pharmaceutical Product Development, Inc, Addicet, Horizon, Atsuko, Sanofi, Shionogi, Novartis, Viela Bio, and MedPace. The other authors report no conflicts.
Databáze: MEDLINE